Acadia Pharmaceuticals

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Simplify's Rating
Why Acadia Pharmaceuticals is rated
B-
Rated C on Competitive Edge
Rated B on Growth Potential
Rated B on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

501-1,000

Company Stage

Acquired

Total Funding

$813.4M

Headquarters

Dallas, Texas

Founded

1993

Overview

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, which are then approved by regulatory bodies like the FDA before being sold to patients and healthcare providers. What sets Acadia apart from competitors is its long-standing commitment to addressing unmet medical needs in neuroscience, along with its emphasis on corporate social responsibility, including diversity and inclusion. The goal of Acadia Pharmaceuticals is to improve the quality of life for individuals suffering from challenging neurological diseases through effective treatments.

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia's recent Health Canada approval for Daybue boosts its market presence in Canada.
  • The exclusive license agreement with Saniona expands Acadia's drug portfolio with SAN711.
  • Hiring Thomas Andrew Garner as CCO strengthens Acadia's commercial leadership team.

What critics are saying

  • Increased competition in CNS drugs may impact Acadia's market share and growth.
  • Regulatory challenges could delay or prevent new drug approvals, affecting revenue.
  • High drug development costs may strain financial resources if trials are unsuccessful.

What makes Acadia Pharmaceuticals unique

  • Acadia focuses on unmet needs in neurological disorders like Parkinson's and Rett syndrome.
  • The company has a strong R&D pipeline with four product candidates in development.
  • Acadia collaborates with partners like Biovail to enhance drug development and commercialization.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$813.4M

Above

Industry Average

Funded Over

0 Rounds

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Company News

Fierce Pharma
Dec 9th, 2024
Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO).

MarketWatch
Nov 26th, 2024
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711

Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.

World Pharmaceuticals
Oct 17th, 2024
Acadia gets Health Canada approval for Daybue to treat Rett Syndrome

US-based biopharmaceutical company Acadia Pharmaceuticals has received Health Canada marketing authorisation for Daybue (trofinetide) to treat a rare genetic neurological disorder.

PRWeb
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

Yahoo Finance
Aug 15th, 2024
Ryan Reynolds Announces More To Parkinson'S(R) Campaign

Ryan & Tammy Reynolds (Photo: Business Wire)Acadia Parkinson's Fact Sheet-- The national disease awareness campaign aims to educate and drive conversation about recognizing and managing non-motor symptoms of Parkinson’s, including hallucinations and delusions-- Reynolds and his mother Tammy share their personal story about the impact of these symptoms on their familySAN DIEGO, August 14, 2024--(BUSINESS WIRE)--Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson’s disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-faceted disease education campaign, More to Parkinson’s®, to raise awareness among caregivers, patients and their care providers about a common, yet under-recognized aspect of Parkinson’s disease – Parkinson’s-related hallucinations and delusions.Notably, around half of the people living with Parkinson’s disease may develop hallucinations or delusions over the course of their disease, but up to 90% of people currently do not proactively tell their physicians about these symptoms.1-3 By sharing their experiences caring for Ryan’s father, James "Jim" Reynolds, who passed away nearly a decade ago, Ryan and his mother Tammy, aim to raise awareness, educate and drive conversation between people with Parkinson’s disease, their families and their doctors about how best to talk about and treat these non-motor symptoms."My father experienced hallucinations and delusions. At the time, we didn’t know any of these types of symptoms were part of his Parkinson’s disease," Reynolds explains. "Like a lot of caregivers, my mom mostly tried to carry these burdens alone. I wish I’d known Parkinson’s disease wasn’t limited to only motor symptoms. I think people and families affected by Parkinson’s can be better prepared to manage hallucinations and delusions if they’re talking early and often about this lesser-known aspect of the disease."This press release features multimedia

Recently Posted Jobs

Sign up to get curated job recommendations

Acadia Pharmaceuticals is Hiring for 0 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Acadia Pharmaceuticals's jobs every 8 hours, so check again soon! Browse all jobs →